GlobalData on MSN12h
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Die Mainzer zahlen einen hohen dreistelligen Millionenbetrag für die Firma Biotheus. Damit verbunden sind Rechte an einem ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and ...
Investor's Business Daily on MSN1h
BioNTech Stock Got A IBD RS Rating LiftHow Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a ...
Das Mainzer Pharmaunternehmen BioNTech übernimmt das chinesische Biotechnologie-Unternehmen Biotheus. BioNTech erweitert ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
Das Mainzer Pharmaunternehmen BioNTech übernimmt das chinesische Biotechnologie-Unternehmen Biotheus. BioNTech erweitert ...
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback